Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 306 entries
Sorted by: Best Match Show Resources per page
NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK.

Drugs in context

Cawston H, Bourhis F, Eriksson J, Ruffo P, D'Agostino P, Turini M, Schwartzberg L, McGuire A.
PMID: 28392826
Drugs Context. 2017 Mar 24;6:212298. doi: 10.7573/dic.212298. eCollection 2017.

BACKGROUND: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting...

Cite
Cawston H, Bourhis F, Eriksson J, et al. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017;6:212298doi: 10.7573/dic.212298.
Cawston, H., Bourhis, F., Eriksson, J., Ruffo, P., D'Agostino, P., Turini, M., Schwartzberg, L., & McGuire, A. (2017). NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs in context, 6212298. https://doi.org/10.7573/dic.212298
Cawston, Helene, et al. "NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK." Drugs in context vol. 6 (2017): 212298. doi: https://doi.org/10.7573/dic.212298
Cawston H, Bourhis F, Eriksson J, Ruffo P, D'Agostino P, Turini M, Schwartzberg L, McGuire A. NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK. Drugs Context. 2017 Mar 24;6:212298. doi: 10.7573/dic.212298. eCollection 2017. PMID: 28392826; PMCID: PMC5378057.
Copy Download .nbib Format: NLM
Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.

Drugs in context

Al-Alaiyan S, Pollack P, Notario GF.
PMID: 25767550
Drugs Context. 2015 Feb 27;4. doi: 10.7573/dic.212270. eCollection 2015.

BACKGROUND: The peak season of respiratory syncytial virus (RSV) infections in warmer climates may extend beyond the typical five-month RSV season of temperate regions. Additional monthly doses of palivizumab may be necessary in warmer regions to protect children at...

Cite
Al-Alaiyan S, Pollack P, Notario GF. Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children. Drugs Context. 2015;4doi: 10.7573/dic.212270.
Al-Alaiyan, S., Pollack, P., & Notario, G. F. (2015). Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children. Drugs in context, 4. https://doi.org/10.7573/dic.212270
Al-Alaiyan, Saleh, et al. "Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children." Drugs in context vol. 4 (2015). doi: https://doi.org/10.7573/dic.212270
Al-Alaiyan S, Pollack P, Notario GF. Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children. Drugs Context. 2015 Feb 27;4. doi: 10.7573/dic.212270. eCollection 2015. PMID: 25767550; PMCID: PMC4353192.
Copy Download .nbib Format: NLM
A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.

Drugs in context

Prasad-Reddy L, Isaacs D.
PMID: 26213556
Drugs Context. 2015 Jul 09;4:212283. doi: 10.7573/dic.212283. eCollection 2015.

The prevalence of type 2 diabetes is increasing at an astounding rate. Many of the agents used to treat type 2 diabetes have undesirable adverse effects of hypoglycemia and weight gain. Glucagon-like peptide-1 (GLP-1) receptor agonists represent a unique...

Cite
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015;4:212283doi: 10.7573/dic.212283.
Prasad-Reddy, L., & Isaacs, D. (2015). A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs in context, 4212283. https://doi.org/10.7573/dic.212283
Prasad-Reddy, Lalita, and Isaacs, Diana. "A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond." Drugs in context vol. 4 (2015): 212283. doi: https://doi.org/10.7573/dic.212283
Prasad-Reddy L, Isaacs D. A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context. 2015 Jul 09;4:212283. doi: 10.7573/dic.212283. eCollection 2015. PMID: 26213556; PMCID: PMC4509428.
Copy Download .nbib Format: NLM
Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Drugs in context

Neumiller JJ.
PMID: 24991224
Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014.

Type 2 diabetes is increasing in prevalence worldwide, and hyperglycemia is often poorly controlled despite a number of therapeutic options. Unlike previously available agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors offer an insulin-independent mechanism for improving blood glucose levels, since...

Cite
Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014;3:212262doi: 10.7573/dic.212262.
Neumiller, J. J. (2014). Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs in context, 3212262. https://doi.org/10.7573/dic.212262
Neumiller, Joshua J. "Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes." Drugs in context vol. 3 (2014): 212262. doi: https://doi.org/10.7573/dic.212262
Neumiller JJ. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context. 2014 Jun 11;3:212262. doi: 10.7573/dic.212262. eCollection 2014. PMID: 24991224; PMCID: PMC4079288.
Copy Download .nbib Format: NLM
Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients.

Drugs in context

Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C.
PMID: 25834621
Drugs Context. 2015 Mar 17;4. doi: 10.7573/dic.212267. eCollection 2015.

OBJECTIVE: Evaluate utilization of inpatient healthcare resources and associated costs after 12 months of treatment using long-acting injectable (LAI) antipsychotic medications among a large sample of Medicaid-insured patients categorized by different age groups.METHOD: Adult patients with schizophrenia were identified...

Cite
Kamat SA, Offord S, Docherty J, et al. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015;4doi: 10.7573/dic.212267.
Kamat, S. A., Offord, S., Docherty, J., Lin, J., Eramo, A., Baker, R. A., Gutierrez, B., & Karson, C. (2015). Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in context, 4. https://doi.org/10.7573/dic.212267
Kamat, Siddhesh A, et al. "Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients." Drugs in context vol. 4 (2015). doi: https://doi.org/10.7573/dic.212267
Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015 Mar 17;4. doi: 10.7573/dic.212267. eCollection 2015. PMID: 25834621; PMCID: PMC4376094.
Copy Download .nbib Format: NLM
Hemodynamic effect of avanafil and glyceryl trinitrate coadministration.

Drugs in context

Swearingen D, Nehra A, Morelos S, Peterson CA.
PMID: 24432037
Drugs Context. 2013 Feb 26;2013:212248. doi: 10.7573/dic.212248. eCollection 2013 Feb 26.

A Phase I, double-blind, randomized, crossover study in healthy males (N=106) was conducted between March 21, 2004, and May 17, 2004, to determine the magnitude and duration of the hemodynamic interaction of avanafil (a phosphodiesterase type-5 inhibitor for treating...

Cite
Swearingen D, Nehra A, Morelos S, et al. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. 2013;2013:212248doi: 10.7573/dic.212248.
Swearingen, D., Nehra, A., Morelos, S., & Peterson, C. A. (2013). Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs in context, 2013212248. https://doi.org/10.7573/dic.212248
Swearingen, Dennis, et al. "Hemodynamic effect of avanafil and glyceryl trinitrate coadministration." Drugs in context vol. 2013 (2013): 212248. doi: https://doi.org/10.7573/dic.212248
Swearingen D, Nehra A, Morelos S, Peterson CA. Hemodynamic effect of avanafil and glyceryl trinitrate coadministration. Drugs Context. 2013 Feb 26;2013:212248. doi: 10.7573/dic.212248. eCollection 2013 Feb 26. PMID: 24432037; PMCID: PMC3884957.
Copy Download .nbib Format: NLM
Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon.

Drugs in context

Schwartz TL, Goradia V.
PMID: 24432044
Drugs Context. 2013 Oct 04;2013:212257. doi: 10.7573/dic.212257. eCollection 2013 Oct 04.

This review explores basic sleep physiology, the mechanism of action for each class of hypnotic agents, their clinical application based on pharmacodynamic and pharmacokinetic factors, and potential pharmacologic sleep-inducing mechanisms of future hypnotics. The paper challenges the reader to...

Cite
Schwartz TL, Goradia V. Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs Context. 2013;2013:212257doi: 10.7573/dic.212257.
Schwartz, T. L., & Goradia, V. (2013). Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs in context, 2013212257. https://doi.org/10.7573/dic.212257
Schwartz, Thomas L, and Goradia, Viral. "Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon." Drugs in context vol. 2013 (2013): 212257. doi: https://doi.org/10.7573/dic.212257
Schwartz TL, Goradia V. Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon. Drugs Context. 2013 Oct 04;2013:212257. doi: 10.7573/dic.212257. eCollection 2013 Oct 04. PMID: 24432044; PMCID: PMC3884958.
Copy Download .nbib Format: NLM
Palbociclib in metastatic breast cancer: current evidence and real-life data.

Drugs in context

Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R.
PMID: 31391852
Drugs Context. 2019 Jul 16;8:212579. doi: 10.7573/dic.212579. eCollection 2019.

The purpose of this review is to summarize the background and latest evidence for the use of palbociclib, an oral, first-in-class, highly selective cyclin-dependent kinase 4/6 inhibitor, in advanced breast cancer, with a focus on some of the unanswered...

Cite
Serra F, Lapidari P, Quaquarini E, et al. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context. 2019;8:212579doi: 10.7573/dic.212579.
Serra, F., Lapidari, P., Quaquarini, E., Tagliaferri, B., Sottotetti, F., & Palumbo, R. (2019). Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs in context, 8212579. https://doi.org/10.7573/dic.212579
Serra, Francesco, et al. "Palbociclib in metastatic breast cancer: current evidence and real-life data." Drugs in context vol. 8 (2019): 212579. doi: https://doi.org/10.7573/dic.212579
Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context. 2019 Jul 16;8:212579. doi: 10.7573/dic.212579. eCollection 2019. PMID: 31391852; PMCID: PMC6668507.
Copy Download .nbib Format: NLM
Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission.

Drugs in context

Tull R, Hoover WD, De Luca JF, Huang WW, Jorizzo JL.
PMID: 30302114
Drugs Context. 2018 Oct 02;7:212529. doi: 10.7573/dic.212529. eCollection 2018.

Eosinophilic fasciitis is an uncommon connective tissue disorder that affects patients of all ages, resulting in significant morbidity. Systemic corticosteroids can induce remission of disease. However, there is no universally accepted treatment ladder for eosinophilic fasciitis. This case series...

Cite
Tull R, Hoover WD, De Luca JF, et al. Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs Context. 2018;7:212529doi: 10.7573/dic.212529.
Tull, R., Hoover, W. D., De Luca, J. F., Huang, W. W., & Jorizzo, J. L. (2018). Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs in context, 7212529. https://doi.org/10.7573/dic.212529
Tull, Rechelle, et al. "Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission." Drugs in context vol. 7 (2018): 212529. doi: https://doi.org/10.7573/dic.212529
Tull R, Hoover WD, De Luca JF, Huang WW, Jorizzo JL. Eosinophilic fasciitis: a case series with an emphasis on therapy and induction of remission. Drugs Context. 2018 Oct 02;7:212529. doi: 10.7573/dic.212529. eCollection 2018. PMID: 30302114; PMCID: PMC6172017.
Copy Download .nbib Format: NLM
The biosimilars journey: current status and ongoing challenges.

Drugs in context

Kos IA, Azevedo VF, Neto DE, Kowalski SC.
PMID: 30302115
Drugs Context. 2018 Oct 01;7:212543. doi: 10.7573/dic.212543. eCollection 2018.

Biosimilar products are already approved and marketed in several countries. The Food and Drug Administration has approved ten different biosimilars, and the European Medicines Agency has approved 40. Even though this scenario has provided important experience with biosimilar products,...

Cite
Kos IA, Azevedo VF, Neto DE, et al. The biosimilars journey: current status and ongoing challenges. Drugs Context. 2018;7:212543doi: 10.7573/dic.212543.
Kos, I. A., Azevedo, V. F., Neto, D. E., & Kowalski, S. C. (2018). The biosimilars journey: current status and ongoing challenges. Drugs in context, 7212543. https://doi.org/10.7573/dic.212543
Kos, Igor Age, et al. "The biosimilars journey: current status and ongoing challenges." Drugs in context vol. 7 (2018): 212543. doi: https://doi.org/10.7573/dic.212543
Kos IA, Azevedo VF, Neto DE, Kowalski SC. The biosimilars journey: current status and ongoing challenges. Drugs Context. 2018 Oct 01;7:212543. doi: 10.7573/dic.212543. eCollection 2018. PMID: 30302115; PMCID: PMC6172013.
Copy Download .nbib Format: NLM
Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system.

Drugs in context

Accurso V, Santoro M, Mancuso S, Napolitano M, Di Piazza F, Russo A, Siragusa SM.
PMID: 30853998
Drugs Context. 2019 Mar 04;8:212569. doi: 10.7573/dic.212569. eCollection 2019.

No abstract available.

Cite
Accurso V, Santoro M, Mancuso S, et al. Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system. Drugs Context. 2019;8:212569doi: 10.7573/dic.212569.
Accurso, V., Santoro, M., Mancuso, S., Napolitano, M., Di Piazza, F., Russo, A., & Siragusa, S. M. (2019). Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system. Drugs in context, 8212569. https://doi.org/10.7573/dic.212569
Accurso, Vincenzo, et al. "Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system." Drugs in context vol. 8 (2019): 212569. doi: https://doi.org/10.7573/dic.212569
Accurso V, Santoro M, Mancuso S, Napolitano M, Di Piazza F, Russo A, Siragusa SM. Efficacy of ruxolitinib retreatment in a patient with high-risk myelofibrosis using the international prognostic scoring system. Drugs Context. 2019 Mar 04;8:212569. doi: 10.7573/dic.212569. eCollection 2019. PMID: 30853998; PMCID: PMC6400146.
Copy Download .nbib Format: NLM
Immunotherapy in non-melanoma skin cancer: updates and new perspectives.

Drugs in context

Ascierto PA, Schadendorf D.
PMID: 30936937
Drugs Context. 2019 Mar 25;8:212583. doi: 10.7573/dic.212583. eCollection 2019.

No abstract available.

Cite
Ascierto PA, Schadendorf D. Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs Context. 2019;8:212583doi: 10.7573/dic.212583.
Ascierto, P. A., & Schadendorf, D. (2019). Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs in context, 8212583. https://doi.org/10.7573/dic.212583
Ascierto, Paolo Antonio, and Schadendorf, Dirk. "Immunotherapy in non-melanoma skin cancer: updates and new perspectives." Drugs in context vol. 8 (2019): 212583. doi: https://doi.org/10.7573/dic.212583
Ascierto PA, Schadendorf D. Immunotherapy in non-melanoma skin cancer: updates and new perspectives. Drugs Context. 2019 Mar 25;8:212583. doi: 10.7573/dic.212583. eCollection 2019. PMID: 30936937; PMCID: PMC6434981.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 306 entries